# Zealand Pharma A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/zealandpharma). ## Overview Zealand Pharma A/S is a Danish biopharmaceutical company focused on discovering and developing peptide-based medicines. Its portfolio centers on drug candidates for metabolic and gastrointestinal diseases, with programs advanced through internal R&D and collaboration agreements. ## Products & services • Peptide therapeutics discovery and development • Obesity and weight-management drug candidates • Gastrointestinal disease programs • Partnered clinical development programs • License and collaboration rights to pipeline assets - **Peptide drug candidates** (70%) — Clinical and preclinical peptide-based medicines for metabolic and gastrointestinal diseases. - **Collaboration revenue** (25%) — Upfront, milestone, and cost-reimbursement revenue from partner agreements. - **License rights and development assets** (5%) — Capitalized rights to co-develop or commercialize partnered drug candidates. - Peptide therapeutics discovery and development - Obesity and weight-management drug candidates - Gastrointestinal disease programs - Partnered clinical development programs - License and collaboration rights to pipeline assets ## Customers Zealand Pharma sells primarily to pharmaceutical partners rather than end patients, with value created through licensing, co-development, and milestone-bearing collaboration agreements. Its commercial counterparties are large biopharma companies that fund development, share costs, and may commercialize products after approval. The underlying end markets are patients and healthcare systems that use treatments for obesity and other chronic metabolic conditions. - **Pharmaceutical collaboration partners** (primary) — Buy development rights, share costs, and pay milestones for Zealand's peptide programs. - **Licensing and co-commercialization partners** (primary) — Access specific assets and commercialization rights under structured agreements. - **Healthcare end users** (secondary) — Patients treated with approved obesity or gastrointestinal therapies developed from the pipeline. - Large pharmaceutical partners funding co-development programs - Biopharma licensees seeking peptide-based assets - Healthcare systems and patients as end-market beneficiaries - Potential commercial partners for approved products - Research collaborators supporting clinical development ## Geography The company is headquartered in Denmark and operates as a global biopharma developer through international collaborations rather than a broad manufacturing footprint. Its reported revenue exposure is shaped by partnership agreements that can generate royalties and milestones across the U.S., Europe, and other markets. Geography matters mainly through where partners commercialize products and where development activities, payments, and currency exposures arise. - Headquartered in Denmark - Revenue is tied to global partnership agreements - Commercialization exposure includes the U.S. and Europe - Development and payment flows create FX exposure - Operations are collaboration-led, not site-intensive ## Strategy Zealand Pharma's strategy is centered on advancing peptide medicines through partnered development, which allows it to share cost, scientific risk, and commercial upside. The Roche collaboration shows the importance of building combination products and milestone-rich agreements that can fund pipeline advancement and broaden eventual commercialization potential. - **Advance key obesity and metabolic programs** (short-term) — Late-stage clinical progress is essential for future milestones, approvals, and commercial value. - **Execute partnered co-development agreements** (medium-term) — Partnerships provide funding, validation, and access to commercialization infrastructure. - **Expand monetization through milestones and royalties** (long-term) — Structured payments diversify funding and create upside tied to clinical and sales success. - Advance peptide pipeline through clinical-stage development - Use partnerships to share R&D cost and commercial risk - Monetize assets through upfronts, milestones, and royalties - Build combination products with larger pharma partners - Focus on obesity and other chronic disease markets ## Risks The business is highly dependent on clinical success, regulatory outcomes, and partner execution, so setbacks can materially affect future revenue and asset values. It also faces concentration risk in a small number of collaboration agreements, together with foreign exchange and valuation risk from milestone structures, derivative contracts, and capitalized intangible assets. - **Clinical development failure** [high] — Pipeline value depends on positive trial results and progression to later stages. - **Partner concentration** [high] — A large share of economics is tied to a limited number of collaboration agreements. - **Foreign exchange volatility** [medium] — Milestones and receivables are linked to USD amounts while reporting is in DKK. - **Intangible asset impairment** [high] — Capitalized license rights depend on continued clinical and commercial viability. - Clinical trial failure could eliminate milestones and reduce asset value - Regulatory delays can push out approval and commercialization timing - Partner concentration increases dependence on a few agreements - FX volatility affects USD-linked milestones and cash balances - Intangible assets may require impairment if programs stall ## Accounting Revenue is driven by collaboration accounting, including upfront allocations, reimbursement for development activities, and milestone recognition when achievement becomes highly probable. The company also uses significant judgment in valuing intangible assets, derivatives, and receivables linked to partner milestones, which can cause large period-to-period swings in reported results. - **Revenue recognition for collaboration agreements** — Can create large, uneven revenue recognition across periods - **Intangible asset capitalization** — Affects balance sheet size and future impairment risk - **Fair value of derivatives** — Introduces volatility in financial items - **Contract assets and trade receivables** — Affects working capital and reported revenue timing - Milestone revenue depends on probability and contractual achievement - Development service revenue is recognized over time as work progresses - Capitalized license rights affect intangible assets and future amortization - FX forwards are measured at fair value through profit or loss - Receivables and contract assets depend on partner billings and milestones --- *Last updated: 2026-10-24T15:21:49.166172+00:00*